The burden of steatotic liver disease
DOI:
https://doi.org/10.52673/18570461.24.2-73.09Keywords:
steatotic liver disease, obesity, diabetes mellitusAbstract
The steatotic liver disease is one of the most common etiologies of chronic liver diseases, especially in developed countries. It is in direct correlation with the prevalence of the metabolic syndrome and the western lifestyle. Thus, we aimed to study the impact of fatty liver disease globally, depending on geographic distribution, age, gender, and associated risk factors, using the searche engines PubMed and Google Scholar. It has been observed that steatotic liver disease is a globally prevalent disease, which is more common in men and post-menopausal women, suggesting the protective role of female sex hormones. Steatotic liver disease is also considered the hepatic manifestation of the metabolic syndrome, being frequently diagnosed among patients with type 2 diabetes and/or obesity. The increased incidence of the disease was also noted in children, overweight / obese adolescents. Steatotic liver disease is a burden both for the patient and society as a whole, requiring the need for screening and early diagnosis.
References
1. Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G, Romero-Gomez, M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. In: Journal of Hepatology, 2020, vol. 73, 202-209. https://doi.org/10.1016/j.jhep.2020.07.045
2. Velarde-Ruiz Velasco, J.A., García-Jiménez, E.S., García-Zermeño, K.R. et al. Extrahepatic complications of non-alcoholic fatty liver disease. In: Rev. Gastroenterol México (English Ed.), 2019, no. 84 (4), 472-481. https://doi.org/10.1016/j.rgmxen.2019.05.004
3. Quek, J., Ng, C.H., Tang, A., Chew, N., Chan, M., Khoo, C.M,. et al. Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals. In: Endocr. Pract., 2022, no. 28 (7), 667-672. https://doi.org/10.1016/j.eprac.2022.03.016
4. Lazarus, J.V., Mark, H.E., Anstee, Q.M., Arab, J.P., Batterham, R.L., Castera, L. et al. Advancing the global public health agenda for NAFLD: a consensus statement. In: Nat Rev. Gastroenterol Hepatol. 2022, no. 19(1), 60-78.
5. Abd El-Kader, S., El-Den, Ashmawy E. Non-alcoholic fatty liver disease: The diagnosis and management. In: World J Hepatol. 2015, no. 7 (6), 846-858. https://doi.org/10.4254/wjh.v7.i6.846
6. Ng, C.H., Huang, D.Q., Nguyen, M.H.. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. In: Clin Mol Hepatol. 2022, no. 28 (4), 790-801. https://doi.org/10.3350/cmh.2022.0070
7. Blomdahl, J., Nasr, P., Ekstedt, M., Kechagias, S. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. In: Metabolism Clinical and Experimental, 2020, vol. 115, 1-5. https://doi.org/10.1016/j.metabol.2020.154439
8. Fouad, Y., Waked, I., Bollipo, S., Gomaa, A., Ajlouni, Y., Attia, D.. What's in a name? Renaming 'NAFLD' to 'MAFLD'. In: Liver International, 2020, vol. 40, 1254-1261. https://doi.org/10.1111/liv.14478
9. Rinella, M.E., Lazarus, J.V., Ratziu, V., Francque, S.M., Sanyal, A.J., Kanwal, F., et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. In: Hepatology, 2023, no. 78(6), 1966-1986.
10. Allen, A.M., Therneau, T.M., Larson, J.J., Coward, A., Somers, V.K., Kamath P.S. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. In: Hepatology, 2018, no. 67(5), 1726-1736. https://doi.org/10.1002/hep.29546
11. Huh, Y., Cho, Y.J., Nam, G.E. Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. In: J. Obes Metab Syndr., 2022, no. 31(1), 17-27, https://doi.org/10.7570/jomes22021
12. Perumpail, B.J., Khan, M.A., Yoo, E.R., Cholankeril, G., Kim, D., Ahmed, A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. In: World J Gastroenterol, 2017, no. 23(47), 8263-8276, https://doi.org/10.3748/wjg.v23.i47.8263
13. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M. Global epidemiology of nonalcoholic fatty liver disease - Meta-analytic assessment of prevalence, incidence, and outcomes. In: Hepatology, 2016, no. 64(1), 73-84, https://doi.org/10.1002/hep.28431
14. Abdel-Rahman, R. Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches. In: Asian Pac J Trop Biomed., 2022, no. 12(3), 99-114, https://doi.org/10.4103/2221-1691.338919
15. Paik, J.M., Golabi, P., Younossi, Y., Mishra, A., Younossi, Z.M. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. In: Hepatology, 2020, no. 72(5), 1605-1616, https://doi.org/10.1002/hep.31173
16. Watt, M.J., Miotto, P.M., De Nardo, W., Montgomery
M.K. The Liver as an Endocrine Organ - Linking NAFLD and Insulin Resistance. In: Endocr Rev., 2019, no. 40(5), 1367-1393, https://doi.org/10.1210/er.2019-00034
17. Yu, C., Wang, M., Zheng, S., Xia, M., Yang, H., Zhang, D., et al. Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study. In: J Clin Transl Hepatol., 2022, no.10(1), 6-16, https://doi.org/10.14218/JCTH.2021.00089
18. Wong, R.J., Cheung, R. Trends in the Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in the United States, 2011-2018. In: Clin Gastroenterol Hepatol., 2022, no. 20(3), 610-613, https://doi.org/10.1016/j.cgh.2021.01.030
19. Chan, K.E., Koh, T., Tang, A., Quek, J., Yong, J., Tay, P., et al. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A meta-analysis and systematic review of 10 739 607 individuals. In: J Clin Endocrinol Metab., 2022, no. 107(9), 2691-2700, https://doi.org/10.1210/clinem/dgac321
20. Kim, D., Kim, W., Kim, H., Therneau, T. Association Between Noninvasive Fibrosis Markers and Mortality Among Adults With Nonalcoholic Fatty Liver Disease in the United States. In: Hepatology, 2013, vol. 57(4), 1357-1365. https://doi.org/10.1002/hep.26156
21. Noureddin, M., Ntanios, F., Malhotra, D., Hoover, K., Emir, B., McLeod, E., et al. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning. In: Hepatol Commun., 2022, 1-12, https://doi.org/10.1002/hep4.1935
22. Kallwitz, E., Daviglus, M., Allison, M., Emory, K., Zhao, L., Kuniholm, M., et al. Prevalence of Suspected Non-alcoholic Fatty Liver Disease in Hispanic/Latino Individuals Differs by Heritage. In: Clinical Gastroenterology and Hepatology, 2015, vol. 13 (3), 569-576, https://doi.org/10.1016/j.cgh.2014.08.037
23. Vidal-Cevallos, P., Torre, A., Mendez-Sanchez, N., Uribe, M., Chavez-Tapia, N.. Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico. In: Clin Liver Dis., 2022, no. 19(2), 68-72, https://doi.org/10.1002/cld.1167
24. Alswat, K., Aljumah, A., Sanai, F., Abaalkhail, F., Alghamdi, M., Al Hamoudi, W., et al. Nonalcoholic fatty liver disease burden-Saudi Arabia and United Arab Emirates, 2017-2030. In: Saudi J Gastroenterol, 2018, 24(4), 211-219, https://doi.org/10.4103/sjg.SJG_122_18
25. Zhou, J., Zhou, F., Wang, W., Zhang, X., Ji, Y., Zhang, P., et al. Epidemiological features of NAFLD from 1999 to 2018 in China. In: Hepatology. John Wiley and Sons Inc, 2020, vol. 71, 1851-1864, https://doi.org/10.1002/hep.31150
26. Lee, H., Kim, B., Kim, S., Park, J., Kim, D., Ahn, S., et al. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. In: Dig Dis Sci. 2017, no. 62(8), 2150-2158, https://doi.org/10.1007/s10620-017-4592-0
27. Caballería, L., Pera, G., Arteaga, I., Rodríguez, L., Alumà, A., Morillas, R., et al. High prevalence of liver fibrosis among european adults with unknown liver disease: a population-based study. In: Clin Gastroenterol Hepatol. 2018, no. 16(7), 1138-1145, https://doi.org/10.1016/j.cgh.2017.12.048
28. Llop, E., Iruzubieta, P., Perelló, C., Fernández Carrillo, C., Cabezas, J., Escudero, M., et al. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort. In: United Eur Gastroenterol J. 2021, no. 9(8), 892-902, https://doi.org/10.1002/ueg2.12109
29. Crespo, J., Iruzubieta, P., Lazarus, J. Can NAFLD overwhelm the Spanish healthcare system in the years to come? In: Rev Esp Enfermedades Dig., 2022, no. 114(1), 5-9.
30. Cholongitas, E., Pavlopoulou, I., Papatheodoridi, M., Markakis, G., Bouras, E., Haidich, A., et al. Epidemiology of nonalcoholic fatty liver disease in Europe: A systematic review and meta-analysis. In: Ann Gastroenterol., 2021, no. 34(3), 404-414 ,https://doi.org/10.20524/aog.2021.0604
31. Peltec A., Ivanov V., Toaca I., Matcovschii S. Cardiovascular risk profile in patients with hepatic steatosis. In: Mold J Heal Sci., 2022, no. 27(1), 17-31, https://doi.org/10.52645/MJHS.2022.1.02
32. Lupașco, I., Dumbrava, V-T, Harea, G., Tocan, A., Ursachii, C., Cebanu, E., et al. Sindromul metabolic și steatoza hepatică. In: Sănătate publică, Econ și Manag în Med., 2016, no. 4 (68), 60-65.
33. Lonardo, A., Suzuki, A. Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research, In: J Clin Med, 2020, vol 9, 1-29, https://doi.org/10.3390/jcm9051278
34. DiStefano, J. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. In: Endocrinology, 2020, vol. 161(10), 1-12, https://doi.org/10.1210/endocr/bqaa134
35. Anderson, E., Howe, L., Jones, H., Higgins, J., Lawlor D., Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. In: Plos One, 2015, no. 10, 1-14, https://doi.org/10.1371/journal.pone.0140908
36. Alfani, R., Vassallo, E. Pediatric Fatty Liver and Obesity: Not always justa matter of non-alcoholic fatty liver disease. In: Children (Basel), 2018, no. 5(12), 1-13, https://doi.org/10.3390/children5120169
37. Neri, C., Scapaticci, S., Chiarelli, F., Giannini, C. Liver Steatosis: a marker of metabolic risk in children. In: Int J Mol Sci., 2022, vol. 23(9), 2-32, https://doi.org/10.3390/ijms23094822
38. Liu, J., Mu, C., Li, K., Luo, H., Liu, Y., Li, Z. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese children and adolescents: systematic review and meta-analysis. In: Int J Public Health, 2021, no. 66, 1-9, https://doi.org/10.3389/ijph.2021.1604371
39. Lin, G., Xinhe, Z., Haoyu, T., Xing, J., Dan, L., Ningning, W., et al. Epidemiology and lifestyle survey of non-alcoholic fatty liver disease in school-age children and adolescents in Shenyang, Liaoning. In: BMC Pediatr., 2022, vol. 22(1), 1-9, https://doi.org/10.1186/s12887-022-03351-w
40. Li, L., Liu, D., Yan, H., Wang, Z., Zhao, S., Wang, B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies. In: Obes Rev., 2016, no. 17(6), 510-519, https://doi.org/10.1111/obr.12407
41. Dai, W., Ye, L., Liu, A., Wen, S., Deng, J., Wu, X., et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. In: Med (United States), 2017, vol. 96(39), 1-8, https://doi.org/10.1097/MD.0000000000008179
42. Rhee, E.J. Nonalcoholic fatty liver disease and diabetes: An epidemiological perspective. In: Endocrinol Metab. 2019, vol. 34(3), 226-233, https://doi.org/10.3803/EnM.2019.34.3.226
43. Koutny, F., Weghuber, D., Bollow, E., Greber-Platzer, S., Hartmann, K., Körner, A, et al. Prevalence of prediabetes and type 2 diabetes in children with obesity and increased transaminases in European German-speaking countries. Analysis of the APV initiative. In: Pediatr Obes. 2020, no. 15(4), 1-8, https://doi.org/10.1111/ijpo.12601
44. Tomah, S., Alkhouri, N., Hamdy, O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? In: Clin. Diabetes Endocrinol., 2020, vol. 6(1), 1-11, https://doi.org/10.1186/s40842-020-00097-1
45. Zeng, J., Qin, L., Jin, Q., Yang, R., Ning, G., Su, Q., et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. In: Hepatobiliary Pancreat Dis Int., 2022, no. 21(2), 154-161, https://doi.org/10.1016/j.hbpd.2022.01.006
46. Valenti, L., Bugianesi, E., Pajvani, U., Targher, G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? In: Liver Int., 2016, no. 36(11), 1563-1579, https://doi.org/10.1111/liv.13185
47. Hazlehurst, J., Woods, C., Marjot, T., Cobbold, J., Tomlinson J. Non-alcoholic fatty liver disease and diabetes. In: Metabolism, 2016, no. 65(8), 1096-1108, https://doi.org/10.1016/j.metabol.2016.01.001
48. Allen, A.M., Lazarus, J., Younossi, Z. Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties. In: J Hepatol., 2023, nr. 79(1), 209-217, https://doi.org/10.1016/j.jhep.2023.01.026
49. Lam, B., Kurzke, K., Younossi, Z. The clinical and economic burden of nonalcoholic steatohepatitis. In: Current Hepatology Reports. Springer. 2018, vol. 17, no. 4, 345-349, https://doi.org/10.1007/s11901-018-0423-9
50. Witkowski, M. et al. The economic burden of non-alcoholic steatohepatitis: a systematic review. In: PharmacoEconomics, 2022, vol. 40, no. 8, 751-776, https://doi.org/10.1007/s40273-022-01140-y
51. O'Hara, J. et al. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. In: JHEP reports : innovation in hepatology, 2020, vol. 2, no. 5, 1-9, https://doi.org/10.1016/j.jhepr.2020.100142
52. Cotter, T.G. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system. In: Journal of Gastroenterology. Springer. 2020, vol. 55, no. 7, 722-730, https://doi.org/10.1007/s00535-020-01684-w
53. Wong, R.J. et al. Real-world comorbidity burden, health care utilization, and costs of nonalcoholic steatohepatitis patients with advanced liver diseases. In: Journal of Clinical Gastroenterology. Lippincott Williams and Wilkins, 2021, vol. 55, no. 10, 891-902, https://doi.org/10.1097/MCG.0000000000001409
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
